Estrella Immunopharma (ESLA) Stock Overview
A clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ESLA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Estrella Immunopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.39 |
| 52 Week High | US$3.15 |
| 52 Week Low | US$0.73 |
| Beta | 0.53 |
| 1 Month Change | -19.19% |
| 3 Month Change | 6.11% |
| 1 Year Change | 12.10% |
| 3 Year Change | -86.47% |
| 5 Year Change | n/a |
| Change since IPO | -85.74% |
Recent News & Updates
Shareholder Returns
| ESLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.7% | -2.0% | -1.1% |
| 1Y | 12.1% | 22.9% | 14.7% |
Return vs Industry: ESLA underperformed the US Biotechs industry which returned 23% over the past year.
Return vs Market: ESLA underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| ESLA volatility | |
|---|---|
| ESLA Average Weekly Movement | 21.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ESLA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ESLA's weekly volatility has increased from 15% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Cheng Liu | www.estrellabio.com |
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. Fundamentals Summary
| ESLA fundamental statistics | |
|---|---|
| Market cap | US$58.91m |
| Earnings (TTM) | -US$13.51m |
| Revenue (TTM) | n/a |
Is ESLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.51m |
| Earnings | -US$13.51m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ESLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 12:33 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Estrella Immunopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |